罕见的凝血因子缺陷的分子方面
Hajar Tourbih1, Asma Harrach2,1, Hanaa Bencharef2,1
1Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, MAR.
Cureus
|August 1, 2025
概括
罕见的遗传凝血因子缺陷会导致出血障碍. 基因分析可以识别致病突变,改善诊断,并为患者指导个性化治疗策略.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 罕见的凝血因子缺陷 (I,II,V,VII,X,XI,XIII因子) 是一种遗传性疾病.
- 这些情况表现为出血症状,严重程度和临床异质性各不相同.
- 在血缘亲属群体中,患病率更高,因此需要了解遗传学.
研究的目的:
- 阐明导致罕见凝血因子缺陷的遗传和分子机制.
- 详细说明诊断方法,包括血液静止测试和分子分析.
- 描述突变类型及其对出血表型的影响.
主要方法:
- 血液静止测试:前列血时间 (PT),激活的部分血栓形成时间 (aPTT),因子活性测试.
- 分子分析:基因组DNA测序 (桑格,下一代测序 - NGS),多重联结依赖探头放大 (MLPA),复制数变异 (CNV) 分析.
- 使用美国医学遗传学和基因组学学院 (ACMG) /分子病理学协会 (AMP) 准则的变体解释.
主要成果:
- 在不同缺陷因子中识别了各种突变 (错误,无意义,拼接,插入/删除).
- 证明突变可以影响因子的生产,结构或分泌.
- 确立了突变类型和出血表型严重程度之间的相关性.
结论:
- 遗传特征显著提高了对凝血障碍的诊断准确度.
- 分子工具为病理生理学提供了更深入的见解,有助于临床管理.
- 多学科的方法和持续的研究对于开发有针对性的疗法至关重要.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
911
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
911
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
01:09Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K
01:16Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K